Milestone Receives FDA Approval of CARDAMYST™ as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia
December 16, 2025
0
Milestone in the NEWS MONTREAL and CHARLOTTE, Milestone® (MIST) announced that the U.S. FDA approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of . . . This content is for paid subscribers. Please click here to subscribe or here to log in.